The rapid increase in antimicrobial resistance (AMR) has turned out to be a giant health danger to the world, and it has compromised the therapeutic effects of traditional antibiotics and the management of routine illnesses. The rapid transmission of resistant strains of microorganisms is forcing the need to come up with new and sustainable antimicrobial measures. Recently, a new category of nanostructured materials with inherent enzyme-like catalytic capabilities was introduced, called nanozymes, and they have become a strong candidate in defeating drug resistance. Their high physicochemical stability, economical nature, and versatile catalytic properties allow them to control bactericidal effects by activating oxidative stress, the formation of reactive oxygen species (ROS), and catalyzing the degradation of bacterial cell components. In contrast to conventional antibiotics, which have a specific biomolecular pathway that is likely to mutate, nanozymes interfere with a variety of cellular activities, which reduces the chances of developing resistance. In addition to this, nanozymes show synergistic reactions with existing antimicrobial agents, which increases their effectiveness and decreases their dosages. They have wide applicability in therapeutic aspects, including biofilm disruption, food preservation, wastewater decontamination, and crop protection. Although they have significant potential, there are still a number of difficulties in translational applications, such as large-scale production, biocompatibility, toxicological evaluation, and regulatory frameworks. To optimize nanozyme design and provide clinical safety, interdisciplinary studies integrating nanotechnology with microbiology and bioengineering should be carried out in the future. As technological progress continues, nanozymes have a huge potential to transform antimicrobial-based therapeutics and reducing the global AMR crisis.